Key statistics
On Friday, NextCure Inc (2US:FRA) closed at 1.21, 22.02% above the 52 week low of 0.99 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.21 |
---|---|
High | 1.21 |
Low | 1.21 |
Bid | 1.17 |
Offer | 1.20 |
Previous close | 1.20 |
Average volume | 0.00 |
---|---|
Shares outstanding | 27.98m |
Free float | 25.46m |
P/E (TTM) | -- |
Market cap | 36.09m USD |
EPS (TTM) | -2.20 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 07:01 GMT.
More ▼
Announcements
- NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
- NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
- NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
- NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
- NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
- NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
- NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
- NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
- NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
More ▼